Bristol Myers Squibb (CELG-RI) Receivables - Other (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Receivables - Other of $108.0 million for Q2 2026, down 93.66% year-over-year from $1.7 billion in Q2 2025, and down 92.41% quarter-over-quarter from $1.4 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Receivables - Other (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Receivables - Other for 18 consecutive years, with $108.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Receivables - Other fell 93.66% year-over-year to $108.0 million; the TTM figure through Jun 2026 stood at $108.0 million (down 93.66% YoY), while the FY2025 annual figure was $1.8 billion, up 4.96% from the prior year.
- Receivables - Other fell to $108.0 million in Q2 2026 per CELG-RI's latest filing, from $1.4 billion in the prior quarter.
- Across five years, Receivables - Other topped out at $2.2 billion in Q1 2023 and bottomed at $108.0 million in Q2 2026.
- Historically, Receivables - Other has averaged $1.3 billion across 5 years, with a median of $1.6 billion in 2022.
- Annual changes were most pronounced in 2023 — Receivables - Other soared 62.36% — and 2026, when it slumped 93.66%.
- Bristol Myers Squibb's Receivables - Other stood at $504.0 million in 2022, then declined by 17.46% to $416.0 million in 2023, then retreated by 7.45% to $385.0 million in 2024, then plunged by 50.13% to $192.0 million in 2025, then sank by 43.75% to $108.0 million in 2026.
- Business Quant data shows CELG-RI's Receivables - Other at $108.0 million in Q2 2026, $1.4 billion in Q1 2026, and $192.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.00 Mn |
| Jun 30, 2026 | 108.00 Mn |
| Mar 31, 2026 | 1.42 Bn |
| Mar 31, 2026 | 1.42 Bn |
| Dec 31, 2025 | 192.00 Mn |
| Dec 31, 2025 | 192.00 Mn |
| Sep 30, 2025 | 1.80 Bn |
| Sep 30, 2025 | 1.80 Bn |
| Jun 30, 2025 | 1.70 Bn |
| Jun 30, 2025 | 1.70 Bn |
| Mar 31, 2025 | 1.74 Bn |
| Mar 31, 2025 | 1.74 Bn |
| Dec 31, 2024 | 385.00 Mn |
| Dec 31, 2024 | 385.00 Mn |
| Sep 30, 2024 | 1.71 Bn |
| Sep 30, 2024 | 1.71 Bn |
| Jun 30, 2024 | 1.68 Bn |
| Jun 30, 2024 | 1.68 Bn |
| Mar 31, 2024 | 1.62 Bn |
| Mar 31, 2024 | 1.62 Bn |